Information for...

General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US Journalists Jobseekers

Value through Innovation

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. OUR FOCUS articulates who we are and what we strive for, how we work and what we want to achieve.

Annual Report Boehringer Ingelheim

Annual Results Report Boehringer Ingelheim

Our Company

Annual Report 2018

Transformation: Developing healthcare solutions for tomorrow

Read moreon

Annual Report 2018

A Unique Bond: human and animal health

Vision & Values

A Unique Bond: human and animal health

Celebrating the truly unique bonds between people and their pets.

Watch the video on

A Unique Bond: human and animal health

Animal Health: One business, one vision, one global leader in disease prevention and treatment

-

Animal Health: A global leader in disease prevention and treatment

We create the future of animal wellbeing. Through our innovative and ground-breaking solutions our highly-skilled employees support all our customers who raise and deeply care for their animals.

Animal Health: A global leader in disease prevention and treatment

Research Beyond Borders

Research & Development

Research Beyond Borders

New ideas and New science. As the Company’s ‘radar’ for the next big wave of innovation find out what the team is doing to explore emerging science and technologies.

Research Beyond Borders

Careers

Working at Boehringer Ingelheim – Being part of a global family

As a research-driven pharmaceutical company Boehringer Ingelheim strives to improve health of people and animals everywhere in the world.

Working at Boehringer Ingelheim – Being part of a global family

Explore Our Content

PRESS RELEASE 04 Sep 2019 at 09:00

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Read more on
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
PRESS RELEASE 03 Sep 2019 at 08:00

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Read more on
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
PRESS RELEASE 26 Aug 2019 at 13:53

Change in the Board of Managing Directors at Boehringer Ingelheim

Read more on
Change in the Board of Managing Directors at Boehringer Ingelheim
PRESS RELEASE 13 Aug 2019 at 09:00

Boehringer Ingelheim opens Health Management Centre in China

Read more on
Boehringer Ingelheim opens Health Management Centre in China
PRESS RELEASE 12 Aug 2019 at 15:00

Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies

Read more on
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
PRESS RELEASE 01 Aug 2019 at 10:00

First half 2019: High levels of investment in R&D and robust organic growth

Read more on
First half 2019: High levels of investment in R&D and robust organic growth
Animal Health

Cartilage from the test tube

Jan Spass, CEO of GST, shares what brought him to develop a ground-breaking treatment of lameness in horses.

Read moreon
Cartilage from the test tube
Animal Health

Microbiome health explained

What exactly is the microbiome, and how can we positively shape it to promote health?

Watch the video on
Microbiome health explained